Scalable Manufacturing of the mAb Intermediate

Next-generation antibody-drug conjugates (ADCs) have benefited from continuing innovation and demonstrated patient benefits.

ADC production begins with the manufacture of the antibody intermediate, which necessitates the development of both upstream and downstream manufacturing capabilities. Join this webinar to explore downstream chromatography scale-up strategies and products at all stages of (monoclonal antibody) mAb intermediate development, from screening to manufacturing.

Key learning objectives

  • Presenting complete solutions for efficient and robust manufacturing of the mAb intermediate
  • Discussing key elements in the purification process, covering hardware from the ÄKTA™ family and resins such as MabSelect PrismA™
  • Covering MabSelect™ VH3 protein A affinity resin for antibody fragments

Who should attend?

  • Process Developer
  • MSAT

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.


Lena Jonsson
Lena Jonsson
Product Strategy Manager<br>Cytiva
Dora Wells
Dora Wells
Content Creator, SelectScience